MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yang, Xiaoqian ^a,b   Lyer, Arun K ^c,d   Singh, Amit ^c   Choy, Edwin ^a   Hornicek, Francis J ^a   Amiji, Mansoor M ^c   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

^c NORTHEASTERN UNIVERSITY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; HYALURONIC ACID; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; PACLITAXEL; SMALL INTERFERING RNA;

ANIMAL; APOPTOSIS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; OVARIAN NEOPLASMS; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR VOLUME; ULTRASTRUCTURE;

ANIMALS; ANTIGENS, CD44; APOPTOSIS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; HYALURONIC ACID; NANOPARTICLES; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923369709     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep08509     Document Type: Article

References (58)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J Clin 64, 9-29 (2014).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J Clin 62, 10-29 (2012).
3. Vaughan, S. et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11, 719-725 (2011).
4. Bast, R. C. Jr., Hennessy, B. & Mills, G. B. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9, 415-428 (2009).
5. Bookman, M.A. et al. Better therapeutic trials in ovarian cancer. JNatl Cancer Inst 106, dju029 (2014).
6. Coleman, R. L., Monk, B. J., Sood, A. K. & Herzog, T. J. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol 10, 211-224 (2013).
7. Banerjee, S. & Kaye, S. B. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 19, 961-968 (2013).
8. Yusuf, R. Z., Duan, Z., Lamendola, D. E., Penson, R. T. & Seiden, M. V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3, 1-19 (2003).
9. Lopez, J., Banerjee, S. & Kaye, S. B. New developments in the treatment of ovarian cancer-future perspectives. Ann Oncol 24 Suppl 10, x69-x76 (2013).
10. Szakacs, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C. & Gottesman, M. M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5, 219-234 (2006).
11. Ali, A. Y. et al. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci 1271, 58-67 (2012).
12. Gottesman, M. M., Fojo, T. & Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2, 48-58 (2002).
13. Higgins, C. F. Multiple molecular mechanisms for multidrug resistance transporters. Nature 446, 749-757 (2007).
14. Johnatty, S. E. et al. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol 131, 8-14 (2013).
15. Arao, S. et al. Expression of multidrug resistance gene and localization of Pglycoprotein in human primary ovarian cancer. Cancer Res 54, 1355-1359 (1994).
16. Materna, V., Pleger, J., Hoffmann, U. & Lage, H. RNA expression of MDR1/Pglycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 94, 152-160 (2004).
17. Holzmayer, T. A., Hilsenbeck, S., Von Hoff, D. D. & Roninson, I. B. Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 84, 1486-1491 (1992).
18. Zajchowski, D. A., Karlan, B. Y. & Shawver, L. K. Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther 11, 492-502 (2012).
19. Rosano, L. et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 17, 2350-2360 (2011).
20. Xiong, X. et al. Sensitization of ovarian cancer cells to cisplatin by gold nanoparticles. Oncotarget 5, 6453-6465 (2014).
21. Wu, H., Hait, W. N. & Yang, J. M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 63, 1515-1519 (2003).
22. Duan, Z., Brakora, K. A. & Seiden, M. V. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 3, 833-838 (2004).
23. Lage, H. MDR1/P-glycoprotein (ABCB1) as target for RNA interferencemediated reversal of multidrug resistance. Curr Drug Targets 7, 813-821 (2006).
24. Pichler, A., Zelcer, N., Prior, J. L., Kuil, A. J. & Piwnica-Worms, D. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin Cancer Res 11, 4487-4494 (2005).
25. Ghosh, S. C., Neslihan Alpay, S. & Klostergaard, J. CD44: a validated target for improved delivery of cancer therapeutics. Expert Opin Ther Targets 16, 635-650 (2012).
26. Skubitz, A. P. Adhesion molecules. Cancer Treat Res 107, 305-329 (2002).
27. Shi, J., Zhou, Z., Di, W. & Li, N. Correlation of CD44v6 expression with ovarian cancer progression and recurrence. BMC Cancer 13, 182 (2013).
28. Hao, J. et al. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 103, 1008-1018 (2010).
29. Chen, H., Hao, J., Wang, L. & Li, Y. Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101, 432-440 (2009).
30. Miletti-Gonzalez, K. E. et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res 65, 6660-6667 (2005).
31. Auzenne, E. et al. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 9, 479-486 (2007).
32. Ganesh, S., Iyer, A. K., Morrissey, D. V. & Amiji, M. M. Hyaluronic acid based selfassembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 34, 3489-3502 (2013).
33. Ganesh, S., Iyer, A. K., Gattacceca, F., Morrissey, D. V. & Amiji, M. M. In vivo biodistribution of siRNA and cisplatin administered using CD44-targeted hyaluronic acid nanoparticles. J Control Release 172, 699-706 (2013).
34. Fojo, T. & Bates, S. Strategies for reversing drug resistance. Oncogene 22, 7512-7523 (2003).
35. Tamaki, A., Ierano, C., Szakacs, G., Robey, R. W. & Bates, S. E. The controversial role of ABC transporters in clinical oncology. Essays Biochem 50, 209-232 (2011).
36. Kelly, R. J. et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 17, 569-580 (2011).
37. Ferry, D. R. Testing the role of P-glycoprotein expression in clinical trials: applying pharmacological principles and best methods for detection together with good clinical trials methodology. Int J Clin Pharmacol Ther 36, 29-40 (1998).
38. Ozols, R. F. et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5, 641-647 (1987).
39. Tai, H. L. Technology evaluation: Valspodar, Novartis AG. Curr Opin Mol Ther 2, 459-467 (2000).
40. Seiden, M. V. et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 86, 302-310 (2002).
41. Green, M. R. et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17, 1263-1268 (2006).
42. Ma, P. & Mumper, R. J. Paclitaxel Nano-Delivery Systems: A Comprehensive Review. J Nanomed Nanotechnol 4, 1000164 (2013).
43. McBride, A. et al. National survey on the effect of oncology drug shortages on cancer care. Am J Health Syst Pharm 70, 609-617 (2013).
44. Bourguignon, L. Y., Peyrollier, K., Xia, W. & Gilad, E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 283, 17635-17651 (2008).
45. Shah, V., Taratula, O., Garbuzenko, O. B., Taratula, O. R., Rodriguez-Rodriguez, L. & Minko, T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res 19, 6193-6204 (2013).
46. Ween, M. P., Oehler, M. K. & Ricciardelli, C. Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis. Int J Mol Sci 12, 1009-1029 (2011).
47. Strobel, T., Swanson, L. & Cannistra, S. A. In vivo inhibition of CD44 limits intraabdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res 57, 1228-1232 (1997).
48. Banzato, A. et al. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res 14, 3598-3606 (2008).
49. Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C. B. & Seed, B. CD44 is the principal cell surface receptor for hyaluronate. Cell 61, 1303-1313 (1990).
50. Duan, Z., Feller, A. J., Penson, R. T., Chabner, B. A. & Seiden, M. V. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5, 3445-3453 (1999).
51. Hutchinson, E. Drug resistance: Destabilizing influence. Nat Rev Cancer 8, 76-77 (2008).
52. Zhang, S., Yu, M., Deng, H., Shen, G. & Wei, Y. Polyclonal rabbit anti-human ovarian cancer globulins inhibit tumor growth through apoptosis involving the caspase signaling. Sci Rep 4, 4984 (2014).
53. Duan, Z., Choy, E., Jimeno, J. M., Cuevas Cdel, M., Mankin, H. J. & Hornicek, F. J. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol 63, 1121-1129 (2009).
54. Duan, Z. et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 12, 5055-5063 (2006).
55. Debernardis, D. et al. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57, 870-874 (1997).
56. Halder, J. et al. Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res 11, 8829-8836 (2005).
57. Chen, H., Landen, C. N., Li, Y., Alvarez, R. D. & Tollefsbol, T. O. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxelresistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Exp Cell Res 319, 697-706 (2013).
58. Duan, Z. et al. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. Clin Cancer Res 18, 4580-4588 (2012).